Showing results (511-520 of 566) with videos related to
Sort By:
Pageof 57
Annals of the Rheumatic Diseases|September 11, 2016
International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trialsAna-Maria Orbai, Maarten de Wit, Philip Mease, et al.The Journal of Rheumatology|August 17, 2017
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016Esi M Morgan, Meredith P Riebschleger, Jennifer Horonjeff, et al.The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: discrimination and feasibilityGeorge Wells, Dorcas E Beaton, Peter Tugwell, et al.Annals of Internal Medicine|November 6, 2002
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trialJoel M Kremer, Mark C Genovese, Grant W Cannon, et al.Annals of the Rheumatic Diseases|February 3, 2011
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma researchChristian Beyer, Jörg H W Distler, Yannick Allanore, et al.Annals of the Rheumatic Diseases|August 21, 2025
EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosusJohanna Mucke, George Bertsias, Martin Aringer, et al.Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic ArthritisLaura C Coates, Oliver FitzGerald, Joseph F Merola, et al.The Journal of Rheumatology|January 17, 2019
Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled TrialsKathleen M Andersen, Jonathan T L Cheah, Lyn March, et al.Journal of Drugs in Dermatology : JDD|December 2, 2025
Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual MeetingSarah Romanelli, Gretchen D Ball, Arianna J Zhang, et al.Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.Pageof 57